Company: NDRA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001654954-25-005770
Chunk: 0

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
ENDRA Life Sciences Inc.

Condensed Consolidated Balance Sheets

  March 31,  December 31,  Assets 2025  2024 Current Assets  (Unaudited)     Cash $2,064,874  $3,229,480 Prepaid expenses  115,332   204,185 Total Current Assets  2,180,206   3,433,665 Non-Current Assets        Fixed assets, net  72,775   69,281 Right of use assets  546,216   578,013 Prepaid expenses, long term  365,417   365,417 Other assets  5,984   5,986 Total Assets $3,170,598  $4,452,362          Liabilities and Stockholders’ Equity        Current Liabilities        Accounts payable and accrued liabilities $439,688  $508,293 Lease liabilities, current portion  126,097   96,937 Total Current Liabilities  565,785   605,230          Long Term Debt        Lease liabilities  461,206   487,482 Warrant Liability  390,722   799,284 Total Long Term Debt  851,928   1,286,766          Total Liabilities  1,417,713   1,891,996          Stockholders’ Equity        Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 17.488 shares issued and outstanding, respectively  -   - Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized;  no shares issued and outstanding  -   - Series C Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding  -   - Common stock, $0.0001 par value; 20,000,000 shares authorized;  562,213 and 536,908 shares issued and outstanding, respectively  55   53 Additional paid in capital  106,227,259   105,998,412 Stock payable  -   - Accumulated deficit